ADC Therapeutics (ADCT) Change in Receivables (2020 - 2026)
ADC Therapeutics (ADCT) posted Change in Receivables of $1.9 million for Q1 2026, down 68.84% sequentially from $6.2 million in Q4 2025, and down 83.15% YoY from $11.4 million in Q1 2025.
ADC Therapeutics (ADCT) Change in Receivables (2020 - 2026) Analysis & Trends
ADC Therapeutics has reported Change in Receivables for 7 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Change in Receivables fell 83.15% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$728000.0 (down 108.4% YoY) and the FY2025 annual result came in at $8.8 million, up 284.22% from the prior year.
- Change in Receivables retreated to $1.9 million in Q1 2026 per ADCT's latest filing, from $6.2 million in the prior quarter.
- Over five years, Change in Receivables peaked at $35.8 million in Q4 2022 and troughed at -$48.9 million in Q1 2023.
- A 5-year average of $53529.4 and a median of -$188000.0 in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 673.68% in 2025, down 1648.28% in 2025.
- Over 5 years, Change in Receivables stood at $35.8 million in 2022, then sank by 88.84% to $4.0 million in 2023, then slumped by 192.87% to -$3.7 million in 2024, then jumped by 266.63% to $6.2 million in 2025, then sank by 68.84% to $1.9 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $1.9 million, $6.2 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | -3.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.01 Mn |
| Jun 30, 2026 | -3.01 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Mar 31, 2026 | 1.93 Mn |
| Dec 31, 2025 | 6.19 Mn |
| Dec 31, 2025 | 6.19 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Sep 30, 2025 | -3.27 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | -3.71 Mn |
| Dec 31, 2024 | -3.71 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | -319,000.00 |
| Jun 30, 2024 | -319,000.00 |
| Mar 31, 2024 | -2.00 Mn |
| Mar 31, 2024 | -2.00 Mn |